The protective effect of pravastatin against coronary heart disease is modified by the leucocyte telomere length of the individual patient

Author：

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1571, 2007-01, pp. : 9-9

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Statins and telomere length: risk assessment and management for coronary heart disease

By Tiwari Atul

Expert Opinion on Therapeutic Targets, Vol. 11, Iss. 7, 2007-07 ,pp. : 979-982

Informa Healthcare

Access to resources Recommend Favorite

Has alcohol been proven to be protective against coronary heart disease?

By Fillmore Kaye Middleton Kerr William Stockwell Tim Chikritzhs Tanya Bostrom Alan

Addiction Research and Theory, Vol. 15, Iss. 1, 2007-01 ,pp. : 35-46

Informa Healthcare

Access to resources Recommend Favorite

Pravastatin: A Pharmacoeconomic Review of its use in Primary and Secondary Prevention of Coronary Heart Disease

By Coukell A.J. Wilde M.I.

PharmacoEconomics, Vol. 14, Iss. 2, 1998-08 ,pp. : 217-236

Adis International

Access to resources Recommend Favorite

The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin

By Rakotoniaina Zo Guerard Pascal Lirussi Frederic Goirand Françoise Rochette Luc Dumas Monique Bardou Marc

Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 374, Iss. 3, 2006-12 ,pp. : 195-206

Springer Publishing Company

Access to resources Recommend Favorite

Hormone replacement therapy: not protective against heart disease?

Inpharma, Vol. 1, Iss. 1310, 2001-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite